MCID: HLL004
MIFTS: 54

Hellp Syndrome

Categories: Blood diseases, Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Hellp Syndrome

MalaCards integrated aliases for Hellp Syndrome:

Name: Hellp Syndrome 12 74 52 58 54 43 15 17 71 32
Hemolysis, Elevated Liver Enzymes, Low Platelets in Pregnancy 58
Hemolysis-Elevated Liver Enzymes-Low Platelets Syndrome 58
Hemolysis, Elevated Liver Enzymes, Lowered Platelets 52

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases
Rare haematological diseases


Summaries for Hellp Syndrome

NIH Rare Diseases : 52 HELLP syndrome is a life-threatening condition that can potentially complicate pregnancy. It is named for 3 features of the condition: H emolysis, E levated L iver enzyme levels, and L ow P latelet levels. It typically occurs in the last 3 months of pregnancy (the third trimester) but can also start soon after delivery. A wide range of non-specific symptoms may be present in women with HELLP syndrome. Symptoms may include fatigue; malaise; fluid retention and excess weight gain; headache; nausea and vomiting; pain in the upper right or middle of the abdomen; blurry vision; and rarely, nosebleed or seizures . The cause of HELLP syndrome is not known, but certain risk factors have been associated with the condition. It is most common in women with preeclampsia or eclampsia . If not diagnosed and treated quickly, HELLP syndrome can lead to serious complications for the mother and baby. The main treatment is to deliver the baby as soon as possible, even if premature, if there is distress of the mother or the baby. Treatment may also include medications needed for the mother or baby, and blood transfusion for severe bleeding problems.

MalaCards based summary : Hellp Syndrome, also known as hemolysis, elevated liver enzymes, low platelets in pregnancy, is related to pre-eclampsia and eclampsia. An important gene associated with Hellp Syndrome is HELLPAR (HELLP Associated Long Non-Coding RNA), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Ibuprofen and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and testes, and related phenotypes are elevated hepatic transaminase and thrombocytopenia

Disease Ontology : 12 A severe pre-eclampsia characterized by hemolysis, elevated liver enzyme and low platelet count.

Wikipedia : 74 HELLP syndrome is a complication of pregnancy characterized by hemolysis, elevated liver enzymes, and a... more...

Related Diseases for Hellp Syndrome

Diseases related to Hellp Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 399)
# Related Disease Score Top Affiliating Genes
1 pre-eclampsia 32.9 VWF SERPINE1 SERPINC1 PGF MTHFR LGALS13
2 eclampsia 31.8 SERPINE1 SERPINC1 PGF MTHFR LGALS13 FLT1
3 pulmonary edema 31.6 SERPINC1 HP F2
4 disseminated intravascular coagulation 31.5 VWF SERPINE1 SERPINC1 GPT F5 F2
5 purpura 31.4 VWF SERPINC1 F2 APOH ADAMTS13
6 placental abruption 31.4 SERPINC1 PGF MTHFR FLT1 F5 F2
7 acute kidney failure 31.3 HP GPT F2 CFH ADAMTS13
8 hepatic infarction 31.3 SERPINC1 GPT F2 APOH
9 severe pre-eclampsia 31.2 SERPINE1 SERPINC1 PGF LGALS13 GPT F5
10 acute liver failure 31.1 SLC17A5 GPT F2
11 cholecystitis 31.1 HP GPT F2
12 hypertensive encephalopathy 31.1 FLT1 F2 ADAMTS13
13 placenta disease 31.0 SERPINC1 PGF MTHFR HADHA FLT1 F5
14 hemoglobinuria 31.0 SERPINC1 HP F2 CFI
15 fatty liver disease, nonalcoholic 1 30.9 SLC17A5 HADHA GPT
16 hepatic coma 30.9 SERPINC1 GPT F2
17 anuria 30.9 HP GPT F2 ADAMTS13
18 thrombophilia 30.8 VWF SERPINE1 SERPINC1 MTHFR F5 F2
19 kidney cortex necrosis 30.8 F2 ADAMTS13
20 hepatic encephalopathy 30.8 SLC17A5 GPT F2
21 enterocolitis 30.8 CFI CFH CD46
22 bilirubin metabolic disorder 30.8 SLC17A5 HP GPT F2 ADAMTS13
23 cholestasis 30.8 SLC17A5 HADHA GPT F2
24 prothrombin-related thrombophilia 30.8 MTHFR F2
25 thrombotic microangiopathy 30.8 VWF HP CFH CD46 ADAMTS13
26 paroxysmal nocturnal hemoglobinuria 30.7 SERPINC1 HP F2 CFI
27 pulmonary embolism 30.7 VWF SERPINE1 SERPINC1 MTHFR F5 F2
28 pregnancy loss, recurrent 1 30.6 MTHFR F5 APOH
29 compartment syndrome 30.6 SLC17A5 SERPINC1 GPT F2
30 mild pre-eclampsia 30.6 PGF LGALS13 FLT1
31 hemolytic anemia 30.5 VWF HP F2 CFI CFH CD46
32 cholangitis 30.5 SLC17A5 HP GPT F2
33 protein s deficiency 30.5 SERPINE1 SERPINC1 MTHFR F5 F2 APOH
34 thrombophilia due to thrombin defect 30.5 SERPINE1 SERPINC1 MTHFR F5 F2 APOH
35 osteonecrosis 30.5 SERPINE1 SERPINC1 MTHFR F2
36 antithrombin iii deficiency 30.5 SERPINC1 MTHFR F5 F2 APOH
37 nonarteritic anterior ischemic optic neuropathy 30.5 SERPINC1 MTHFR F5 F2 APOH
38 budd-chiari syndrome 30.5 SERPINC1 MTHFR F5 F2 APOH
39 retinal vascular disease 30.4 PGF MTHFR FLT1
40 cerebral palsy 30.4 SERPINE1 SERPINC1 MTHFR F5 F2
41 placental insufficiency 30.4 VWF SERPINE1 SERPINC1 PGF FLT1 F2
42 thrombotic thrombocytopenic purpura 30.4 VWF SERPINC1 HP CFI CFH CD46
43 hemolytic-uremic syndrome 30.4 VWF SERPINC1 HP F2 CFI CFH
44 hemolytic uremic syndrome, atypical 1 30.4 VWF HP CFI CFH CD46 ADAMTS13
45 thrombophilia due to activated protein c resistance 30.4 VWF SERPINE1 SERPINC1 MTHFR F5 F2
46 antiphospholipid syndrome 30.3 VWF SERPINE1 SERPINC1 PGF MTHFR F5
47 thrombosis 30.3 VWF SERPINE1 SERPINC1 MTHFR F5 F2
48 retinal vein occlusion 30.3 SERPINE1 SERPINC1 MTHFR F5 F2 APOH
49 lipoprotein quantitative trait locus 30.3 VWF SERPINE1 HP GPT F2
50 thrombocytopenia 30.2 VWF SERPINE1 SERPINC1 MTHFR HP GPT

Graphical network of the top 20 diseases related to Hellp Syndrome:



Diseases related to Hellp Syndrome

Symptoms & Phenotypes for Hellp Syndrome

Human phenotypes related to Hellp Syndrome:

58 31 (show all 33)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 elevated hepatic transaminase 58 31 obligate (100%) Obligate (100%) HP:0002910
2 thrombocytopenia 58 31 obligate (100%) Obligate (100%) HP:0001873
3 proteinuria 58 31 frequent (33%) Frequent (79-30%) HP:0000093
4 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
5 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
6 prolonged prothrombin time 58 31 frequent (33%) Frequent (79-30%) HP:0008151
7 preeclampsia 58 31 frequent (33%) Frequent (79-30%) HP:0100602
8 increased body weight 58 31 frequent (33%) Frequent (79-30%) HP:0004324
9 generalized edema 58 31 frequent (33%) Frequent (79-30%) HP:0007430
10 hypofibrinogenemia 58 31 frequent (33%) Frequent (79-30%) HP:0011900
11 maternal hypertension 58 31 frequent (33%) Frequent (79-30%) HP:0008071
12 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
13 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
14 back pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0003418
15 hypotension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002615
16 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
17 eclampsia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100601
18 pulmonary edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0100598
19 disseminated intravascular coagulation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005521
20 hemoglobinuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0003641
21 poor wound healing 58 31 occasional (7.5%) Occasional (29-5%) HP:0001058
22 nausea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002018
23 microangiopathic hemolytic anemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001937
24 epigastric pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0410019
25 shoulder pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0030834
26 placental abruption 58 31 occasional (7.5%) Occasional (29-5%) HP:0011419
27 decreased mean corpuscular hemoglobin concentration 58 31 occasional (7.5%) Occasional (29-5%) HP:0025547
28 increased lactate dehydrogenase level 31 occasional (7.5%) HP:0025435
29 cerebral hemorrhage 58 31 very rare (1%) Very rare (<4-1%) HP:0001342
30 acute kidney injury 58 31 very rare (1%) Very rare (<4-1%) HP:0001919
31 hemolytic anemia 58 Very frequent (99-80%)
32 internal hemorrhage 58 Very rare (<4-1%)
33 increased lactate dehydrogenase activity 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Hellp Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.9 CD46 CFH F2 F5 FLT1 HADHA
2 homeostasis/metabolism MP:0005376 9.83 ADAMTS13 APOH CFH CFI F2 F5
3 mortality/aging MP:0010768 9.44 ADAMTS13 APOH CFH F2 F5 FLT1

Drugs & Therapeutics for Hellp Syndrome

Drugs for Hellp Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ibuprofen Approved Phase 4 15687-27-1 3672
2
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
6 Ketorolac Tromethamine Phase 4
7 Anti-Arrhythmia Agents Phase 4
8 Anticonvulsants Phase 4
9 Anti-Inflammatory Agents Phase 4
10 Gastrointestinal Agents Phase 4
11 Pharmaceutical Solutions Phase 4
12 Antineoplastic Agents, Hormonal Phase 4
13 Antiemetics Phase 4
14 Hormone Antagonists Phase 4
15 HIV Protease Inhibitors Phase 4
16
protease inhibitors Phase 4
17 glucocorticoids Phase 4
18 BB 1101 Phase 4
19
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
20
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
21
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
22
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
23
Enoxaparin Approved Phase 3 9005-49-6 772
24
Dalteparin Approved Phase 3 9005-49-6
25
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
26
Misoprostol Approved Phase 3 59122-46-2 5282381
27
Carbetocin Approved, Investigational Phase 3 37025-55-1 71715 16681432
28
Oxytocin Approved, Vet_approved Phase 3 50-56-6 53477758 439302
29
Tranexamic Acid Approved Phase 3 1197-18-8 5526
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
31
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
32
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
33
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
34
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
35
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
36 Tocotrienol Investigational Phase 3 6829-55-6
37 Phosphodiesterase Inhibitors Phase 2, Phase 3
38 Citrate Phase 2, Phase 3
39 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3
40 Sildenafil Citrate Phase 2, Phase 3 171599-83-0
41 Antipyretics Phase 3
42 Cyclooxygenase Inhibitors Phase 3
43 Analgesics, Non-Narcotic Phase 3
44 Antirheumatic Agents Phase 3
45 Anti-Inflammatory Agents, Non-Steroidal Phase 3
46 Antioxidants Phase 3
47 Tocotrienols Phase 3
48 Protective Agents Phase 3
49 Tocopherols Phase 3
50 Fibrinolytic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Unknown status NCT02920593 Phase 4 Vitamin D3
2 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Unknown status NCT02911701 Phase 4 Acetaminophen;Ibuprofen
3 Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
4 Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial. Completed NCT03164304 Phase 4 Magnesium Sulfate
5 Postpartum Dexamethasone for Women With Class I HELLP Syndrome: a Double-blind, Placebo-controled, Randomized Clinical Trial Terminated NCT00711841 Phase 4 dexamethasone;Placebo;dexamethasone
6 Dexamethasone Efficacy in HELLP I Syndrome, a Multicentric, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01138839 Phase 3 Dexamethasone;sterile water
7 Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial Unknown status NCT03262961 Phase 2, Phase 3 Sildenafil 20 MG;Placebo Oral Tablet
8 Calcium for Pre-Eclampsia Prevention (CPEP) Completed NCT00000534 Phase 3 calcium
9 RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil Completed NCT00097110 Phase 3 Vitamin C and E
10 Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial Completed NCT00986765 Phase 3 Lovenox® (enoxaparin);Aspegic ® (Aspirin)
11 Carbetocin in Preventing Postpartum Bleeding in Women With Severe Preeclampsia. Completed NCT02086994 Phase 3 misoprostol;carbetocin
12 Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section Active, not recruiting NCT03463993 Phase 3 Tranexamic Acid;Oxytocin
13 Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART) Active, not recruiting NCT00920621 Phase 3
14 Maternal and Neonatal Outcomes After the Use of Vasopressors to Correct Hypotension During Cesarean Section Under Spinal Anesthesia in Pregnant Women With Severe Preeclampsia: Randomized Clinical Trial Withdrawn NCT01451060 Phase 3 Metaraminol;Ephedrine
15 Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET) Withdrawn NCT00293735 Phase 2, Phase 3 labetalol (seizure prevention);MgSO4 (seizure prevention)
16 Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
17 Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE) Not yet recruiting NCT04402385 Phase 2 Aspirin 81 mg;Placebo
18 Effect of Rosuvastatin on Sever Preeclampsia Induced Inflammatory Response Not yet recruiting NCT04303806 Phase 2 rosuvastatin
19 Usefulness of Extracorporeal Removal of sFlt-1 in Women With Severe Preeclampsia at Less Than 26 Weeks' Gestation Terminated NCT02286284 Phase 2
20 Treatment Targets for Chronic Hypertension in Pregnancy Withdrawn NCT00194974 Phase 1, Phase 2 methyldopa;labetalol;nifedipine;clonidine
21 Eculizumab in HELLP Syndrome Not yet recruiting NCT04103489 Phase 1 Eculizumab
22 Sublingual Microcirculation Change in Pregnant Women With or Without High Risk Pregnancy Factors During Pregnancy and Postpartum Period Unknown status NCT03476096
23 The Predictive Use of Spot Urine Protein/Creatinine Ratios and Decreased Sample Collection Time in the Diagnosis of Preeclampsia Unknown status NCT00870428
24 General Anesthesia Versus Spinal Anesthesia in Patients of HELLP Syndrome Completed NCT03111446
25 Association Between the Quantitative Assessment of Schistocytes in Peripheral Blood Smear and Prognosis of Patient Initially Diagnosed as HELLP Syndrome. Completed NCT03246542
26 Investigation of the Serum MUC3 Protein Levels in Gestational Hypertensive Disease (Preeclampsia-Eclampsia, Pregnancy Induced Hypertension, and HELLP Syndrome) Compared With Normal Pregnancy Completed NCT04421183
27 Dynamics of Serum Immunologic Markers Levels in During the Delivery and Possible Benefit for Obstetric Emergency Diagnostics Completed NCT03664999
28 Assessment of Immature Platelet Fraction in Pregnancy-Associated Thrombotic Microangiopathy Completed NCT03232359
29 Correlation of the Driving Pressure With the Survival of Puerperae Under Mechanical Ventilation by Electrical Impedance Tomography Completed NCT03715647
30 Screening for Placental Insufficiency by a Combination of Second Trimester Uterine Artery Doppler and Maternal Serum Leptin and Lipids Completed NCT00465634
31 A Comparison of B Type Natriuretic Peptide Levels and Hemodynamics Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women - A Pilot Study Completed NCT02527018
32 Comparative Study of Plasma Free DNA and Nucleosome Concentrations: Pathological Versus Normal Pregnancies Completed NCT01736826
33 Platelet Count Trends in Pre-eclamptic Parturients: What is the Predictive Value of an Initial Platelet Count During Labor? Completed NCT00787241
34 "Pre-eclampsia/Eclampsia in Italy Over the Years 2010-2016" Retrospective Observational Multicenter Study Carried Out Through an On-line Self-administered Questionnaire Completed NCT02982265
35 Early Vascular Adjustments to Prevent Preeclampsia and Related Complications Completed NCT04216706 tailored pharmaceutical treatment
36 Maternal Serum Level of ACTH as a Predictive Marker of Preterm Labor in Patients With Threatened Preterm Labor Completed NCT01773135
37 The Clinical Utility of the Congo-Red Dot Test for Diagnosis and Early Prediction of Preeclampsia During Pregnancy Completed NCT02455544
38 Measurement of B Lymphocyte Stimulator (BLyS) in Peripheral Blood From Pregnant and Nonpregnant Women Completed NCT03364712
39 The Effectiveness of a Freeze All Protocol Versus Fresh Embryo Transfer in Women Undergoing In-vitro Fertilization (IVF) - Intracytoplasmic Sperm Injection (ICSI) Completed NCT02471573
40 Detection and Identification of Preeclampsia Via Volatile Biomarkers Completed NCT01291342
41 Retrospective Investigation of Presence of Urobilinogen and Maternal Weight Loss as Indications of Impending Parturition in the Term Gravida Completed NCT00826605
42 Placental Growth Factor as a Predictor of Adverse Pregnancy Outcomes in Preeclamptic Women in Abakaliki Completed NCT04374604
43 Analysis of Serum Pancreatic Stone Protein (PSP) in Healthy Pregnant Women and Its Value in Predicting Inflammatory Complications During Pregnancy Recruiting NCT02247297
44 A Observational Study to Determine the Prevalence of Pregnancy-related Thrombotic Thrombocytopenic Purpura and Atypical Haemolytic Uraemic Syndrome in Women Affected by Specific Obstetric Complications Recruiting NCT03605511
45 Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy. Recruiting NCT03455387
46 EASL: European Registry of Liver Disease in Pregnancy Recruiting NCT03834285
47 Genetic Polymorphisms of ABCB11 and ABCB4 in Women With Intrahepatic Cholestasis of Pregnancy (ICP) and in Their First Degree Relatives Recruiting NCT04281082 ursofalk
48 MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo Recruiting NCT04389099
49 Women Specific Cardiac Recovery After Preeclampsia Recruiting NCT02807324
50 The Preeclampsia Registry Recruiting NCT02020174

Search NIH Clinical Center for Hellp Syndrome

Cochrane evidence based reviews: hellp syndrome

Genetic Tests for Hellp Syndrome

Anatomical Context for Hellp Syndrome

MalaCards organs/tissues related to Hellp Syndrome:

40
Liver, Kidney, Testes, Placenta, Endothelial, Brain, Lung

Publications for Hellp Syndrome

Articles related to Hellp Syndrome:

(show top 50) (show all 2259)
# Title Authors PMID Year
1
Conservative versus active management in HELLP syndrome: results from a cohort study. 52 61
29228827 2019
2
The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with HELLP syndrome. 61 54
18058192 2009
3
Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. 54 61
19190814 2009
4
Acute fatty liver of pregnancy and neonatal long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) deficiency. 54 61
18408953 2009
5
Maternal factor V Leiden mutation is associated with HELLP syndrome in Caucasian women. 54 61
18568463 2008
6
HELLP syndrome is associated with an increased inflammatory response, which may be inhibited by administration of prednisolone. 61 54
18696354 2008
7
The presence of active von Willebrand factor under various pathological conditions. 54 61
17414220 2007
8
Reduced pseudocholinesterase activity in patients with HELLP syndrome. 54 61
17636231 2007
9
Neither maternal nor fetal mutation (E474Q) in the alpha-subunit of the trifunctional protein is frequent in pregnancies complicated by HELLP syndrome. 61 54
17313315 2007
10
Characteristic laboratory changes in pregnancies complicated by HELLP syndrome. 61 54
18066958 2007
11
Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. 54 61
16968329 2006
12
Maternal heterozygosity for a mitochondrial trifunctional protein mutation as a cause for liver disease in pregnancy. 61 54
15533621 2005
13
Lack of correlation between fatty acid oxidation disorders and haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome? 61 54
15858960 2005
14
Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. 54 61
15516393 2004
15
Pseudocholinesterase deficiency associated with HELLP syndrome. 61 54
15311366 2004
16
[Pregnancy complicated by HELLP syndrome]. 54 61
15884197 2004
17
Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. 54 61
12969811 2003
18
Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. 61 54
14526324 2003
19
Anticardiolipin and anti-beta2-glycoprotein-I antibodies in preeclampsia. 61 54
12907102 2003
20
[Pregnancy and inborn errors of metabolism]. 54 61
12931456 2003
21
[Antiphospholipid antibodies in HELLP syndrome: clinical and biological study in 68 women]. 61 54
12657437 2003
22
The evaluation of maternal parameters at diagnosis may predict HELLP syndrome severity. 61 54
12820835 2003
23
Haptoglobin and its association with the HELLP syndrome. 61 54
12624142 2003
24
Correlation of platelet count changes with liver cell destruction in HELLP syndrome. 54 61
12648443 2003
25
Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. 61 54
12519104 2002
26
Gestational thrombocytopenia and pregnancy-induced antithrombin deficiency: progenitors to the development of the HELLP syndrome and acute fatty liver of pregnancy. 54 61
12536342 2002
27
ProC Global assay in the evaluation of women with history of severe preeclampsia or HELLP syndrome. 61 54
12518722 2002
28
[The impact of pregnancy-prolonging management on maternal and neonatal morbidity in HELLP syndrome]. 61 54
11709744 2001
29
[Hemolytic uremic syndrome in twin pregnancy at 32 weeks gestation with HELLP syndrome. Case report]. 54 61
11431643 2001
30
Serum soluble Fas in the syndrome of hemolysis, elevated liver enzymes, and low platelets. 61 54
11506848 2001
31
Hyperhomocysteinaemia: a risk factor for preeclampsia? 61 54
11301178 2001
32
A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia. 54 61
11283205 2001
33
HELLP syndrome and factor V Leiden. 54 61
11267721 2001
34
Doppler velocimetry and non stress test in severe fetal growth restriction. 61 54
11332586 2001
35
Efficacy of haptoglobin administration in the early postoperative course of patients with a diagnosis of HELLP syndrome. 54 61
15512676 2000
36
Liver disease in pregnancy and fetal fatty acid oxidation defects. 61 54
11001809 2000
37
Heterozygosity for the common LCHAD mutation (1528g>C) is not a major cause of HELLP syndrome and the prevalence of the mutation in the Dutch population is low. 54 61
10926288 2000
38
Methylenetetrahydrofolate reductase polymorphisms in preeclampsia and the HELLP syndrome. 61 54
11118403 2000
39
Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. 61 54
10877984 2000
40
Association of a decrease in antithrombin III activity with a perinatal elevation in aspartate aminotransferase in women with twin pregnancies: relevance to the HELLP syndrome. 61 54
10207801 1999
41
Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. 61 54
10331463 1999
42
Can the laboratory assay of protein C activity assist in monitoring the hemostatic function in pre-eclampsia? 61 54
10357006 1999
43
Plasma glutathione S-transferase Pi 1-1 measurements in the study of hemolysis in hypertensive disorders of pregnancy. 54 61
10476616 1999
44
Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. 61 54
9721789 1998
45
Triplet pregnancy complicated by a gradual decline in antithrombin-III activity and HELLP syndrome: a case report. 61 54
9798357 1998
46
Extensive hepatic infarction caused by thrombosis of right portal vein branches and arterial vasospasm in HELLP syndrome associated with homozygous factor V Leiden. 61 54
9517665 1998
47
Inherited metabolic diseases affecting the carrier. 61 54
9061562 1997
48
Eclampsia after polychemotherapy for nodal-positive breast cancer during pregnancy. 54 61
8841812 1996
49
Reproductive effects of maternal metabolic disorders: implications for pediatrics and obstetrics. 54 61
8827903 1996
50
[Lactate dehydrogenase isoenzymes in patients with HELLP syndrome]. 61 54
8963883 1996

Variations for Hellp Syndrome

Expression for Hellp Syndrome

Search GEO for disease gene expression data for Hellp Syndrome.

Pathways for Hellp Syndrome

Pathways related to Hellp Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.56 VWF SERPINE1 SERPINC1 F5 F2
2 11.39 VWF SERPINE1 SERPINC1 F5 F2 CFI
3
Show member pathways
10.36 PGF FLT1

GO Terms for Hellp Syndrome

Cellular components related to Hellp Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.9 VWF SERPINE1 SERPINC1 HP GSTP1 GPT
2 extracellular region GO:0005576 9.77 VWF SERPINE1 SERPINC1 PGF HP GSTP1
3 endoplasmic reticulum lumen GO:0005788 9.73 SERPINC1 F5 F2 ADAMTS13
4 collagen-containing extracellular matrix GO:0062023 9.72 VWF SERPINE1 SERPINC1 F2 APOH
5 blood microparticle GO:0072562 9.56 SERPINC1 HP F2 CFH
6 platelet alpha granule lumen GO:0031093 9.54 VWF SERPINE1 F5
7 extracellular space GO:0005615 9.44 SERPINE1 SERPINC1 PGF HP GSTP1 GPT
8 platelet alpha granule GO:0031091 9.4 VWF F5

Biological processes related to Hellp Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.77 VWF SERPINC1 F5 F2 ADAMTS13
2 platelet degranulation GO:0002576 9.73 VWF SERPINE1 F5 APOH
3 regulation of complement activation GO:0030449 9.71 F2 CFI CFH CD46
4 platelet activation GO:0030168 9.67 VWF F2 ADAMTS13
5 blood coagulation, intrinsic pathway GO:0007597 9.5 VWF F2 APOH
6 vascular endothelial growth factor signaling pathway GO:0038084 9.48 PGF FLT1
7 negative regulation of blood coagulation GO:0030195 9.46 SERPINE1 APOH
8 positive regulation of blood coagulation GO:0030194 9.43 SERPINE1 F2 APOH
9 regulation of blood coagulation GO:0030193 9.33 SERPINC1 F2 APOH
10 negative regulation of fibrinolysis GO:0051918 9.13 SERPINE1 F2 APOH
11 hemostasis GO:0007599 9.02 VWF SERPINC1 F5 F2 ADAMTS13

Molecular functions related to Hellp Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.13 VWF SERPINE1 SERPINC1
2 heparin binding GO:0008201 9.02 SERPINC1 PGF F2 CFH APOH

Sources for Hellp Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....